Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc Investor and Analyst Event at ASH Transcript

Dec 12, 2022 / 01:30PM GMT
Release Date Price: €3.65 (-16.64%)
Elhan Webb
Karyopharm Therapeutics Inc. - SVP of IR

Good morning, everyone, and thank you all for joining us today for Karyopharm's Analyst Event at ASH. Following our webcast today, the slides being presented here will be made available on the Investors section of our website. I'm joined today by my colleague, Richard Paulson, President and CEO; Dr. Reshma Rangwala, Chief Medical Officer. I'm also very pleased to be joined today by 2 recognized global thought leaders in the area of MPN, Dr. Verstovsek and Dr. Ali.

On this slide is an outline of what we will cover today. Before we begin, I'd like to remind you that various remarks we'll make today constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 as outlined here.

It is now my pleasure to introduce Richard Paulson, President and CEO of Karyopharm. Richard?

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Thank you, Elhan, and good morning to everyone. And we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot